Your browser doesn't support javascript.
loading
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence.
Krasniqi, Eriseld; Pizzuti, Laura; Barchiesi, Giacomo; Sergi, Domenico; Carpano, Silvia; Botti, Claudio; Kayal, Ramy; Sanguineti, Giuseppe; Marchetti, Paolo; Botticelli, Andrea; Marinelli, Daniele; Gamucci, Teresa; Natoli, Clara; Grassadonia, Antonino; Tinari, Nicola; Tomao, Silverio; Tonini, Giuseppe; Santini, Daniele; Michelotti, Aandrea; Mentuccia, Lucia; Vaccaro, Aangela; Magnolfi, Emanuela; Gelibter, Alain; Magri, Valentina; Cortesi, Enrico; D'Onofrio, Loretta; Cassano, Alessandra; Cazzaniga, Marina; Moscetti, Luca; Fabbri, Agnese; Scinto, Angelo Fedele; Corsi, Domenico; Carbognin, Luisa; Bria, Emilio; La Verde, Nicla; Garufi, Carlo; Di Stefano, Pia; Mirabelli, Rossana; Veltri, Enzo; Paris, Ida; Giotta, Francesco; Lorusso, Vito; Landucci, Elisa; Ficorella, Corrado; Roselli, Mario; Adamo, Vincenzo; Ricciardi, Giuseppina; Russo, Antonio; Valerio, Maria Rosaria; Berardi, Rossana.
Afiliación
  • Krasniqi E; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Pizzuti L; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Barchiesi G; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Sergi D; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Carpano S; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Botti C; Department of Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Kayal R; Department of Radiology and Diagnostic Imaging, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Sanguineti G; Department of Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Marchetti P; Medical Oncology Unit B, Policlinico Umberto I, Rome, Italy.
  • Botticelli A; Department of Clinical and Molecular Medicine, Azienda Ospedaliera Sant'Andrea, "Sapienza" University of Rome, Rome, Italy.
  • Marinelli D; Medical Oncology Unit B, Policlinico Umberto I, Rome, Italy.
  • Gamucci T; Department of Clinical and Molecular Medicine, Azienda Ospedaliera Sant'Andrea, "Sapienza" University of Rome, Rome, Italy.
  • Natoli C; Medical Oncology, Sandro Pertini Hospital, Rome, Italy.
  • Grassadonia A; Department of Medical, Oral and Biotechnological Sciences and CeSI-MeT, G. D'Annunzio University, Chieti, Italy.
  • Tinari N; Department of Medical, Oral and Biotechnological Sciences and CeSI-MeT, G. D'Annunzio University, Chieti, Italy.
  • Tomao S; Department of Medical, Oral and Biotechnological Sciences and CeSI-MeT, G. D'Annunzio University, Chieti, Italy.
  • Tonini G; Department of Radiological, Oncological and Anatomo-Pathological Sciences, Policlinico Umberto I, 'Sapienza' University of Rome, Rome, Italy.
  • Santini D; Department of Oncology, University Campus Biomedico of Rome, Rome, Italy.
  • Michelotti A; Department of Oncology, University Campus Biomedico of Rome, Rome, Italy.
  • Mentuccia L; Dipartimento di Oncologia, Dei Trapianti e Delle Nuove Tecnologie, UO Oncologia Medica I, S. Chiara Hospital, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
  • Vaccaro A; Medical Oncology Unit, ASL Frosinone, Frosinone, Italy.
  • Magnolfi E; Medical Oncology Unit, ASL Frosinone, Frosinone, Italy.
  • Gelibter A; Medical Oncology Unit, ASL Frosinone, Frosinone, Italy.
  • Magri V; Medical Oncology Unit B, Policlinico Umberto I, Rome, Italy.
  • Cortesi E; Medical Oncology Unit B, Policlinico Umberto I, Rome, Italy.
  • D'Onofrio L; Medical Oncology Unit B, Policlinico Umberto I, Rome, Italy.
  • Cassano A; Department of Oncology, University Campus Biomedico of Rome, Rome, Italy.
  • Cazzaniga M; Department of Medical Oncology, Policlinico Universitario "A. Gemelli", Rome, Italy.
  • Moscetti L; Research Unit Phase I Trials and Oncology Unit, ASST Monza, Monza, Italy.
  • Fabbri A; Division of Medical Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
  • Scinto AF; Medical Oncology Unit, Belcolle Hospital, Viterbo, Italy.
  • Corsi D; Medical Oncology Unit, Fatebenefratelli Hospital, Rome, Italy.
  • Carbognin L; Medical Oncology Unit, Fatebenefratelli Hospital, Rome, Italy.
  • Bria E; University of Verona, Verona, Italy.
  • La Verde N; Division of Gynecologic Oncology, Department of Woman and Child Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
  • Garufi C; University of Verona, Verona, Italy.
  • Di Stefano P; Comprehensive Cancer Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica Del Sacro Cuore, Roma, Italy.
  • Mirabelli R; Oncology Unit, ASST Fatebenefratelli Sacco Presidio Ospedaliero Fatebenefratelli, Milano, Italy.
  • Veltri E; Medical Oncology, "Santo Spirito" Hospital, Pescara, Italy.
  • Paris I; Medical Oncology, "Santo Spirito" Hospital, Pescara, Italy.
  • Giotta F; Department of Hematology & Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy.
  • Lorusso V; Oncology Unit, S. Maria Goretti Hospital, Latina, Italy.
  • Landucci E; Division of Gynecologic Oncology, Department of Woman and Child Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
  • Ficorella C; Department of Medical Oncology, "Giovanni Paolo II" Institute, Bari, Italy.
  • Roselli M; Department of Medical Oncology, "Giovanni Paolo II" Institute, Bari, Italy.
  • Adamo V; Dipartimento di Oncologia, Dei Trapianti e Delle Nuove Tecnologie, UO Oncologia Medica I, S. Chiara Hospital, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
  • Ricciardi G; Department of Biotechnological and Applied Clinical Sciences, Medical Oncology, University of L'Aquila, L'Aquila, Italy.
  • Russo A; Department of Systems Medicine, Medical Oncology, University of Rome "Tor Vergata", Rome, Italy.
  • Valerio MR; Department of Human Pathology, Medical Oncology Unit A.O. Papardo, University of Messina, Messina, Italy.
  • Berardi R; Department of Human Pathology, Medical Oncology Unit A.O. Papardo, University of Messina, Messina, Italy.
J Cell Physiol ; 235(11): 7900-7910, 2020 11.
Article en En | MEDLINE | ID: mdl-31943171
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Anticuerpos Monoclonales Humanizados / Antineoplásicos Inmunológicos / Ado-Trastuzumab Emtansina / Obesidad Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: J Cell Physiol Año: 2020 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Anticuerpos Monoclonales Humanizados / Antineoplásicos Inmunológicos / Ado-Trastuzumab Emtansina / Obesidad Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: J Cell Physiol Año: 2020 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Estados Unidos